Finance

Lists
BLTE:NASDAQ
Belite Bio Inc
154,49 US$
+1,29%
(+1,97) 1D
154,49 US$
0,00% (0,00)
After hours
Closed: 9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLTE...
Open
152,73 US$
High
155,99 US$
Low
152,17 US$
Mkt. cap
6,22 მლრდ.
Avg. vol.
192,63 ათ.
Volume
179,30 ათ.
52-wk high
200,00 US$
52-wk low
77,68 US$
EPS
-2,85 US$
Beta
-1,23
Shares outstanding
40,27 მლნ.
No. of employees
41
Open
152,73 US$
High
155,99 US$
Low
152,17 US$
Mkt. cap
6,22 მლრდ.
Avg. vol.
192,63 ათ.
Volume
179,30 ათ.
52-wk high
200,00 US$
52-wk low
77,68 US$
EPS
-2,85 US$
Beta
-1,23
Shares outstanding
40,27 მლნ.
No. of employees
41
News stories
From web sources and news partners
About Belite Bio Inc
CEO-
Employees41
Founded2016
Headquarters-
SectorPharmaceutical industry
Websitebelitebio.com
Analyst ratings
Based on 7 analysts giving stock ratings to BLTE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BLTE in the last 3 months.
Highest
Current 154,49 US$
303,00 US$ (+96,13%)
Average
236,86 US$ (+53,32%)
Lowest
200,00 US$ (+29,46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
234,00 US$
+51,5%
09/09/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
245,00 US$
+58,6%
09/09/2026
Whitney Ijem
Canaccord Genuity
Buy
Initiated
303,00 US$
+96,1%
09/04/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
200,00 US$
+29,5%
09/02/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
206,00 US$
+33,3%
08/17/2026
Michael Okunewitch
Maxim Group
Buy
Maintained
200,00 US$
+29,5%
08/14/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
270,00 US$
+74,8%
08/14/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
217,00 US$
+40,5%
03/03/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,31 მლნ.
14,62 მლნ.
15,66 მლნ.
18,21 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,71 მლნ.
13,45 მლნ.
17,02 მლნ.
16,69 მლნ.
Operating expense
23,02 მლნ.
28,08 მლნ.
32,68 მლნ.
34,91 მლნ.
Total operating expenses
23,02 მლნ.
28,08 მლნ.
32,68 მლნ.
34,91 მლნ.
Operating income
-23,02 მლნ.
-28,08 მლნ.
-32,68 მლნ.
-34,91 მლნ.
Other non operating income
-2,14 მლნ.
-417,00 ათ.
5,75 მლნ.
6,55 მლნ.
EBT including unusual items
-21,69 მლნ.
-25,32 მლნ.
-26,94 მლნ.
-28,36 მლნ.
EBT excluding unusual items
-21,69 მლნ.
-25,32 მლნ.
-26,94 მლნ.
-28,36 მლნ.
Income tax expense
-
-
-
55,00 ათ.
Effective tax rate
-
-
-
-0,19%
Other operating expenses
-
-
-
-
Net income
-21,69 მლნ.
-25,32 მლნ.
-26,94 მლნ.
-28,41 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,65
-0,70
-0,68
-0,70
Interest and investment income
3,47 მლნ.
3,17 მლნ.
-
-
Interest expense
-
-2,00 ათ.
-
-
Net interest expenses
3,47 მლნ.
3,17 მლნ.
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,97 მლნ.
-28,03 მლნ.
-32,64 მლნ.
-34,86 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები